Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease

Title: Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease
Authors: Crispo, James A. G.
Willis, Allison W.
Thibault, Dylan P.
Fortin, Yannick
Hays, Harlen D.
McNair, Douglas S.
Bjerre, Lise M.
Kohen, Dafna E.
Perez-Lloret, Santiago
Mattison, Donald R.
Krewski, Daniel
Date: 2016
Abstract: Background Elderly adults should avoid medications with anticholinergic effects since they may increase the risk of adverse events, including falls, delirium, and cognitive impairment. However, data on anticholinergic burden are limited in subpopulations, such as individuals with Parkinson disease (PD). The objective of this study was to determine whether anticholinergic burden was associated with adverse outcomes in a PD inpatient population. Methods Using the Cerner Health Facts® database, we retrospectively examined anticholinergic medication use, diagnoses, and hospital revisits within a cohort of 16,302 PD inpatients admitted to a Cerner hospital between 2000 and 2011. Anticholinergic burden was computed using the Anticholinergic Risk Scale (ARS). Primary outcomes were associations between ARS score and diagnosis of fracture and delirium. Secondary outcomes included associations between ARS score and 30-day hospital revisits. Results Many individuals (57.8%) were prescribed non-PD medications with moderate to very strong anticholinergic potential. Individuals with the greatest ARS score (≥4) were more likely to be diagnosed with fractures (adjusted odds ratio (AOR): 1.56, 95% CI: 1.29–1.88) and delirium (AOR: 1.61, 95% CI: 1.08–2.40) relative to those with no anticholinergic burden. Similarly, inpatients with the greatest ARS score were more likely to visit the emergency department (adjusted hazard ratio (AHR): 1.32, 95% CI: 1.10–1.58) and be readmitted (AHR: 1.16, 95% CI: 1.01–1.33) within 30-days of discharge. Conclusions We found a positive association between increased anticholinergic burden and adverse outcomes among individuals with PD. Additional pharmacovigilance studies are needed to better understand risks associated with anticholinergic medication use in PD.
DOI: 10.1371/journal.pone.0150621
CollectionPublications en libre accès financées par uOttawa // uOttawa financed open access publications
journal.pone.0150621.PDF268.54 kBAdobe PDFOpen